Barry-Wehmiller spins up CARR Biosystems

New venture in global bioprocessing equipment will enable biopharmaceutical partners to solve complex problems to realize groundbreaking advances in medicine

  • CARR Biosystems

Clearwater, FL — Aug. 4, 2022 — To meet the demand of rapidly accelerating growth in the bioprocessing space, Barry-Wehmiller is launching a new business, CARR Biosystems, which will focus on its long-standing centrifugal separation systems capabilities.

Formerly CARR Centritech, a brand of Pneumatic Scale Angelus -- one of Barry-Wehmiller’s well-known packaging divisions -- the centrifuge product lines of both stainless steel and single-use separation systems will now operate as an independent business. The new CARR Biosystems company will serve customers in both emerging and established markets, such as cell and gene therapy, vaccine development, biologics, proteins, microbial fermentation, and cellular agriculture.

With almost 30 years of experience delivering versatile, industry-leading products that accelerate process development, CARR Biosystems delivers high-performance, fully-scalable separation solutions from early-stage development to commercial manufacturing.

“Life-saving advances are made possible by robust processes,” said Carol O’Neill, Barry-Wehmiller’s Group President, Packaging, who also will oversee the CARR Biosystems business. “With our centrifugation solutions, we are empowering scientists and engineers to produce vital biologics. It has always been central to Barry-Wehmiller’s culture to measure our success by the way we touch the lives of people. We think there is no business more poised to do that in a meaningful way than CARR Biosystems.”

Joel Williams joins the CARR Biosystems team as President of the newly-formed business. Williams most recently served as President of the Pharmaceutical and Advanced Technology Business Group of ILC Dover, a leader in single-use technologies for Biotherapeutic applications. A graduate of Harvard Business School, with degrees in Materials Science and Engineering from MIT and Mechanical Engineering from Brigham Young, his technical aptitude and expertise as a business builder position him to lead CARR Biosystems in meeting the growing demand for innovation in biotherapeutic processing.

“I’m excited to help customers discover how CARR Biosystems can increase production yield and viability in their shear-sensitive therapies,” Williams said. “CARR centrifuges accelerate development for life-saving and life-changing treatments by making it easy to scale from development to commercial production.”

The CARR Biosystems team will meet with customers at the Bioprocessing Summit in Boston, Aug. 15-18, and ACHEMA in Frankfurt, Aug. 22-26 to help them understand the fit between their needs and CARR Biosystems’ range of separation solutions.

For more information regarding our centrifugal separation systems, please visit or e-mail